"Vancomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
| Descriptor ID |
D014640
|
| MeSH Number(s) |
D09.400.420.925 D12.644.233.925
|
| Concept/Terms |
Vancocin- Vancocin
- Vancocin HCl
- Vancomycin Lilly
- Vancocine
|
Below are MeSH descriptors whose meaning is more general than "Vancomycin".
Below are MeSH descriptors whose meaning is more specific than "Vancomycin".
This graph shows the total number of publications written about "Vancomycin" by people in this website by year, and whether "Vancomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 2 | 5 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 2 | 4 |
| 2006 | 3 | 1 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 1 | 3 |
| 2009 | 4 | 0 | 4 |
| 2011 | 2 | 4 | 6 |
| 2012 | 2 | 7 | 9 |
| 2013 | 6 | 1 | 7 |
| 2014 | 3 | 2 | 5 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 5 | 7 |
| 2017 | 4 | 7 | 11 |
| 2018 | 6 | 2 | 8 |
| 2019 | 4 | 2 | 6 |
| 2020 | 4 | 3 | 7 |
| 2021 | 1 | 2 | 3 |
| 2022 | 3 | 6 | 9 |
| 2023 | 0 | 2 | 2 |
| 2024 | 4 | 2 | 6 |
| 2025 | 7 | 4 | 11 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vancomycin" by people in Profiles.
-
Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients. Crit Care Explor. 2024 10 01; 6(10):e1159.
-
Optimizing Vancomycin Dosing and Monitoring in Neonates and Infants Using Population Pharmacokinetic Modeling. Antimicrob Agents Chemother. 2022 04 19; 66(4):e0189921.
-
Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteraemia?- A retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2021 Jul; 40(7):1503-1510.
-
Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis. Infection. 2021 Oct; 49(5):803-811.
-
Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and Adolescents. Pediatrics. 2020 09; 146(3).
-
Population Pharmacokinetics of Vancomycin in the Pediatric Ventricular Assist Device Population. Pediatr Crit Care Med. 2020 08; 21(8):e566-e571.
-
Vancomycin Should Be Part of Empiric Therapy for Suspected Bacterial Meningitis. J Pediatric Infect Dis Soc. 2019 May 11; 8(2):187-188.
-
Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy. Eur J Clin Pharmacol. 2019 Aug; 75(8):1089-1097.
-
Population Pharmacokinetic Assessment of Vancomycin Dosing in the Large Pediatric Patient. Antimicrob Agents Chemother. 2019 04; 63(4).
-
Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness. Clin Infect Dis. 2019 01 18; 68(3):365-372.